Document is current
Any future updates will be listed below
-
Authors
Farenc, Christine
Clot, Pierre-Francois
Badalamenti, Salvatore
Kruger, Annie J.
Pomponio, Robert J.
Krahnke, Tillmann
Staudinger, Heribert
Lin, Yong
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 6 January 2025
Accepted: 20 May 2025
First Online: 19 June 2025
Declarations
:
: All authors (Christine Farenc, Pierre-Francois Clot, Salvatore Badalamenti, Annie J. Kruger, Robert J. Pomponio, Tillmann Krahnke, Heribert Staudinger, Yong Lin) were employees of Sanofi at the time this study was conducted and may hold shares/stocks in the company.
: The study protocol was approved by independent ethics committee (The Medical Research Ethics Committee of the ‘Stichting Beoordeling Ethiek Biomedisch Onderzoek’ [Foundation of Ethics in Biomedical Research], Assen, The Netherlands) and/or institutional review boards and was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonization guidelines for Good Clinical Practice. The participants were informed of the risks and benefits of the trial, and that they could withdraw from the trial at any time for any reason. Written informed consent was obtained from all the participants before any study-related interventions were administered.
